المؤلفون: Le Flohic E; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.; Dauphine University, Paris, France., Vrijens B; University of Liège, Liège, Belgium.; AARDEX Group, Liège, Belgium., Hiligsmann M; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

المصدر: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Aug; Vol. 90 (8), pp. 1984-2003. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase II as Topic* , Clinical Trials, Phase III as Topic* , Randomized Controlled Trials as Topic*, Humans ; Medication Adherence/statistics & numerical data ; Product Surveillance, Postmarketing

المؤلفون: Luke JJ; UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. Electronic address: lukejj@upmc.edu., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore Hospital, and Mater Hospital, 40 Rocklands Road, North Sydney, NSW 2065, Australia., Robert C; Gustave Roussy and Paris-Saclay University, 114 Rue Edouard Vaillant, Paris, Villejuif, France., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2065, Australia., Choueiri TK; Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Haas NB; Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA., O'Brien M; Royal Marsden Hospital and Imperial College, Downs Rd, Sutton, SM2 5PT London, United Kingdom., Paz-Ares L; Complutense University, Cancer Network Biomedical Research Center Consortium (CIBERONC), Spanish National Caner Research Center (CNIO) and Hospital 12 de Octubre, Madrid, Spain., Peters S; Lausanne University Hospital Center (CHUV) and University of Lausanne, Quartier Centre, 1015 Lausanne, Switzerland., Powles T; St Bartholomew's Hospital, West Smithfield, London EC1A 7B, United Kingdom., Leiby MA; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Lin J; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Zhao Y; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Krepler C; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Perini RF; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Catherine Pietanza M; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Samkari A; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Gruber T; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Ibrahim N; Merck & Co., Inc., 126 E Lincoln Avenue, Rahway, NJ 07065, USA., Eggermont AMM; Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, Université Paris-Sud, 114 Rue Edouard Vaillant, Villejuif, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Aug; Vol. 207, pp. 114146. Date of Electronic Publication: 2024 May 31.

نوع المنشور: Journal Article; Clinical Trial, Phase III

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Melanoma*/drug therapy , Melanoma*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/therapeutic use , Clinical Trials, Phase III as Topic*, Humans ; Male ; Female ; Chemotherapy, Adjuvant ; Aged ; Middle Aged ; Adult ; Young Adult ; Aged, 80 and over ; Adolescent

المؤلفون: Sherry AD; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Msaouel P; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kouzy R; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Abi Jaoude J; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Radiation Oncology, Stanford University, Stanford, CA, United States., Lin TA; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Taniguchi CM; Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fuller CD; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Minsky B; Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ludmir EB; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

المصدر: The oncologist [Oncologist] 2024 Jul 05; Vol. 29 (7), pp. 547-550.

نوع المنشور: Journal Article; Editorial; Comment

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase III as Topic*/standards , Kaplan-Meier Estimate*, Humans ; Neoplasms/therapy ; Medical Oncology/standards ; Medical Oncology/methods

المؤلفون: Villacampa G; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: https://twitter.com/G_Villacampa., Dennett S; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Mello E; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Holton J; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Lai X; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Kilburn L; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Bliss J; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Rekowski J; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK., Yap C; Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK. Electronic address: christina.yap@icr.ac.uk.

المصدر: ESMO open [ESMO Open] 2024 Jul; Vol. 9 (7), pp. 103603. Date of Electronic Publication: 2024 Jun 25.

نوع المنشور: Journal Article; Systematic Review

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase III as Topic* , Neoplasms*/drug therapy , Neoplasms*/therapy, Humans ; Randomized Controlled Trials as Topic ; Medical Oncology/standards ; Sample Size ; Chemotherapy, Adjuvant/methods

المؤلفون: Li Y; Department of Statistics, University of Illinois Urbana-Champaign, Champaign, Illinois, USA., Zhang Y; Department of Biostatistics and Programming, Sanofi US, Cambridge, Massachusetts, USA., Mi G; Department of Biostatistics and Programming, Sanofi US, Cambridge, Massachusetts, USA., Lin J; Department of Biostatistics and Programming, Sanofi US, Cambridge, Massachusetts, USA.

المصدر: Statistics in medicine [Stat Med] 2024 Aug 15; Vol. 43 (18), pp. 3383-3402. Date of Electronic Publication: 2024 Jun 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 8215016 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0258 (Electronic) Linking ISSN: 02776715 NLM ISO Abbreviation: Stat Med Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase II as Topic*/methods , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/therapeutic use , Drug Development*/methods , Clinical Trials, Phase III as Topic*, Humans ; Sample Size ; Computer Simulation ; Dose-Response Relationship, Drug ; Research Design ; United States ; United States Food and Drug Administration ; Drug Approval ; Randomized Controlled Trials as Topic ; Neoplasms/drug therapy

المؤلفون: Shefner JM; Barrow Neurological Institute, Phoenix, AZ, USA., Cudkowicz ME; Massachusetts General Hospital, Boston, MA, USA.

المصدر: Annals of neurology [Ann Neurol] 2024 Aug; Vol. 96 (2), pp. 211-215. Date of Electronic Publication: 2024 Jun 18.

نوع المنشور: Journal Article; Editorial

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE

مواضيع طبية MeSH: Amyotrophic Lateral Sclerosis*/therapy , Clinical Trials, Phase III as Topic*/methods, Humans ; Biomedical Research

المؤلفون: Bergenstal RM; International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA., Philis-Tsimikas A; Scripps Whittier Diabetes Institute, Scripps Health, San Diego, California, USA., Wysham C; Rockwood Center for Diabetes and Endocrinology, Spokane, Washington State, USA., Carr MC; Eli Lilly and Company, Indianapolis, Indiana, USA., Bue-Valleskey JM; Eli Lilly and Company, Indianapolis, Indiana, USA., Botros FT; Eli Lilly and Company, Indianapolis, Indiana, USA., Blevins T; Texas Diabetes and Endocrinology, Austin, Texas, USA., Rosenstock J; Velocity Clinical Research at Medical City, Dallas, Texas, USA.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 (8), pp. 3020-3030. Date of Electronic Publication: 2024 Apr 28.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Hypoglycemic Agents*/administration & dosage , Hypoglycemic Agents*/therapeutic use , Drug Administration Schedule* , Clinical Trials, Phase III as Topic* , Diabetes Mellitus, Type 1*/drug therapy , Diabetes Mellitus, Type 1*/blood , Insulin, Long-Acting*/administration & dosage , Insulin, Long-Acting*/therapeutic use, Humans ; Blood Glucose/drug effects ; Blood Glucose/analysis ; Glycated Hemoglobin/analysis ; Glycated Hemoglobin/drug effects ; Adult ; Insulin Glargine/administration & dosage ; Insulin Glargine/therapeutic use ; Randomized Controlled Trials as Topic ; Female ; Male ; Research Design ; Insulin/administration & dosage ; Insulin/therapeutic use ; Multicenter Studies as Topic ; Middle Aged

المؤلفون: Landre T; Unité d'Oncologie et Gériatrie, HUPSSD, Hôpital René Muret, AP-HP, Sevran, France., Assié JB; Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France.; Université de Paris-Est Créteil, Créteil, France.; Functional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris Cité, Paris, France., Chouahnia K; Servie d'Oncologie, HUPSSD, Hôpital Avicenne, AP-HP, Bobigny, France., Des Guetz G; Service d'Oncologie, Centre Hospitalier Delafontaine, Saint-Denis, France., Auliac JB; Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France., Chouaïd C; Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France.; Inserm U955, UPEC, IMRB, Créteil, France.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Aug; Vol. 24 (8), pp. 775-780. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Meta-Analysis; Comparative Study; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , ErbB Receptors*/genetics , Randomized Controlled Trials as Topic* , Mutation* , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Clinical Trials, Phase III as Topic*, Humans ; Survival Rate

المؤلفون: Moyer H; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Mellett R; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Vigneault K; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., McKeown M; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Karlawish J; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Augustine E; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Schneider L; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles., Kimmelman J; From the Department of Equity, Ethics and Policy (H.M., R.M., K.V., M.M., J. Kimmelman), McGill University, Montreal, Quebec, Canada; Penn Memory Center (J. Karlawish), University of Pennsylvania, Philadelphia; Clinical Trials Unit (E.A.), Kennedy Krieger Institute, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences and Neurology, Keck School of Medicine (L.S.), and L. Davis School of Gerontology (L.S.), University of Southern California, Los Angeles.

المصدر: Neurology [Neurology] 2024 Jul 09; Vol. 103 (1), pp. e209533. Date of Electronic Publication: 2024 Jun 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase II as Topic*/methods , Clinical Trials, Phase III as Topic*/methods , Nervous System Diseases*/drug therapy , Nervous System Diseases*/epidemiology, Humans ; Drug Development/methods ; Prevalence

المؤلفون: Philippidis A; Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.

المصدر: Human gene therapy [Hum Gene Ther] 2024 Jul; Vol. 35 (13-14), pp. 413-415.

نوع المنشور: News; Journal Article

بيانات الدورية: Publisher: M.A. Liebert Country of Publication: United States NLM ID: 9008950 Publication Model: Print Cited Medium: Internet ISSN: 1557-7422 (Electronic) Linking ISSN: 10430342 NLM ISO Abbreviation: Hum Gene Ther Subsets: MEDLINE

مواضيع طبية MeSH: Muscular Dystrophy, Duchenne*/therapy , Clinical Trials, Phase III as Topic* , Genetic Therapy*/methods, Humans ; Male ; Drug Industry ; Child